31 March 2012
Results of liver transplantation in the treatment of Budd-Chiari syndrome
Anna MackiewiczBEF, Marcin KotulskiCEF, Krzysztof ZieniewiczAD, Marek KrawczykADOI: 10.12659/AOT.882630
Ann Transplant 2012; 17(1): 5-10
Abstract
Background: Budd-Chiari syndrome (BCS) is a rare disorder which can lead to liver failure. It arises from an occlusion of small vessels and/or thrombosis of the major hepatic veins. Polycythemia vera is believed to be one of the most common factors causing BCS. In cases not responding to other measures, liver transplantation may be a successful method of radical treatment.
The purpose of this study was to assess the value and results of liver transplantation in the treatment of Budd-Chiari syndrome.
Material/Methods: This retrospective study included all the cases of LTx (liver transplantation) performed because of BCS in the Department of General, Transplant and Liver Surgery, Medical University of Warsaw and it covered the period from 2000 to 2009. Twenty-four patients (8 men, 16 women) with the average age of 33±11 presented with BCS, 6 patients (25%) underwent previous surgical therapy, 2 patients were treated by mesocaval “H” anastomosis (portosystemic shunts) and 4 patients received TIPSS (transjugular intrahepatic portosystemic shunt) prior to LTx. Polycythemia vera was an underlying risk factor in 11 cases. Two patients needed early retransplantation (re-LTx). In immunosuppressive therapy, schema with glucocorticosteroids and FK-506 predominated.
Results: Four cases of bleeding to peritoneal cavity requiring surgical intervention were observed; 3 patients died in the early post-transplant period due to multiorgan failure and 1 late death occurred because of internal causes. Actual survival rate was 83% at 5 years.
Conclusions: In the late stage, Budd-Chiari syndrome should be considered as an indication for liver transplantation, especially when other measures such as porto-systemic shunts are scarce and ineffective.
Keywords: Transjugular intrahepatic portosystemic shunt (TIPSS), Liver Transplantation, Budd-Chiari syndrome, Liver failure
In Press
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
18 Mar 2024 : Original article
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of R...Ann Transplant In Press; DOI: 10.12659/AOT.943282
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860